Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/23/2025

Medications to Improve Gastric Emptying

Primary Prokinetic Agent

  • Metoclopramide is the first-line medication to improve gastric emptying, as it is the only FDA-approved prokinetic agent for gastroparesis and has the strongest evidence base for accelerating gastric emptying in both diabetic and idiopathic gastroparesis 1
  • Metoclopramide 5-20 mg three to four times daily (taken 30 minutes before meals and at bedtime) is the standard dosing for gastroparesis 1
  • Metoclopramide carries a black box warning for tardive dyskinesia with prolonged use (>12 weeks), so treatment duration should be limited and patients monitored for extrapyramidal symptoms 1

Alternative Prokinetic Agents

  • Domperidone 10-20 mg three to four times daily is an effective alternative, though only available in the U.S. through FDA investigational drug protocol 1
  • Domperidone has a lower risk of central nervous system side effects compared to metoclopramide because it does not cross the blood-brain barrier as readily 1
  • Doses of domperidone above 10 mg three times daily are not recommended due to risk of QT prolongation 1
  • Erythromycin accelerates gastric emptying by binding to motilin receptors and stimulating cholinergic activity in the antrum 2
  • Erythromycin is typically used as a second-line agent when metoclopramide fails or cannot be tolerated 2
  • Tachyphylaxis (loss of effectiveness) commonly develops with chronic use of erythromycin, limiting its long-term utility 2
  • Prucalopride, a selective 5-HT4 receptor agonist, showed promise in a small RCT by accelerating gastric emptying and improving symptoms and quality of life in both diabetic and idiopathic gastroparesis 2, 3
  • Velusetrag, another highly selective 5-HT4 receptor agonist, accelerated gastric emptying in a large phase 2 RCT without apparent cardiac side effects, though phase 3 trials have not been announced 2, 3

Medications That Should NOT Be Used

  • Avoid GLP-1 receptor agonists in patients with gastroparesis, as they further delay gastric emptying and exacerbate symptoms 4
  • Avoid opioid analgesics for chronic abdominal pain in gastroparesis patients, as they further delay gastric emptying and worsen the underlying condition 5
  • Avoid synthetic cannabinoids (dronabinol, nabilone) despite their antiemetic properties, as they have the potential to slow gastric emptying 2